Significant Ownership of Vestal Point Capital, LP

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for Vestal Point Capital, LP focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager location
New York, NY
Manager signature
/s/ Ryan Wilder - By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner

Follow Filing Activity

Follow Vestal Point Capital, LP with Pro and return when a new Schedule 13D/G filing changes the record on this page.

Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.

Review Pro alert access Already have an account? Sign in and return here

Significant Ownership of Vestal Point Capital, LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TENX TENAX THERAPEUTICS, INC. Common Stock, par value $0.0001 per share 9.9% $18,525,720 2,470,096 Vestal Point Capital, LP 30 Sep 2024
APRE Aprea Therapeutics, Inc. Common Stock, par value $0.001 per share 9.9% 22,654,832 Vestal Point Capital, LP 31 Mar 2026
BCAX Bicara Therapeutics Inc. Common Stock, par value $0.0001 per share 8.3% $120,109,500 +$40,959,000 5,425,000 +52% Vestal Point Capital, LP 31 Mar 2026
IBIO iBio, Inc. Common Stock, par value $0.001 per share 7.9% $5,836,250 -$362,500 4,025,000 -5.8% Vestal Point Capital, LP 30 Jun 2026
NRIX Nurix Therapeutics, Inc. Common Stock, par value $0.001 per share 7.8% $192,958,500 +$37,153,500 8,050,000 +24% Vestal Point Capital, LP 30 Jun 2026
LXEO Lexeo Therapeutics, Inc. Common Stock, par value $0.0001 per share 7.5% $27,338,885 +$5,903,896 4,117,302 +28% Vestal Point Capital, LP 30 Sep 2025
TSHA Taysha Gene Therapies, Inc. Common Stock, par value $0.00001 per share 6.3% $80,460,000 +$18,997,500 18,000,000 +31% Vestal Point Capital, LP 31 Mar 2026
MYGN MYRIAD GENETICS INC Common Stock, par value $0.01 per share 6.1% $33,607,100 5,735,000 Vestal Point Capital, LP 30 Jun 2026
ELVN Enliven Therapeutics, Inc. Common Stock, par value $0.001 per share 5.4% $147,290,000 -$26,285,600 3,250,000 -15% Vestal Point Capital, LP 31 Mar 2026
GLUE Monte Rosa Therapeutics, Inc. Common Stock, par value $0.0001 per share 5.4% $110,676,000 4,600,000 Vestal Point Capital, LP 30 Jun 2026
CBIO CRESCENT BIOPHARMA, INC. Ordinary Shares, par value $0.001 per share 5.4% $16,575,000 1,500,000 Vestal Point Capital, LP 31 Dec 2025
DAWN Day One Biopharmaceuticals, Inc. Common Stock, par value $0.0001 per share 5.1% $55,068,000 5,200,000 Vestal Point Capital, LP 31 Dec 2025
DRUG BRIGHT MINDS BIOSCIENCES INC. Common Shares, no par value 5% $41,133,252 492,319 Vestal Point Capital, LP 31 Mar 2026
SLDB Solid Biosciences Inc. Common Stock, par value $0.001 per share 4.8% $46,984,497 -$9,537,303 4,833,796 -17% Vestal Point Capital, LP 30 Jun 2026
IMTX Immatics N.V. Ordinary Shares, nominal value 0.01 per share 4.6% $65,022,750 -$1,053,000 6,175,000 -1.6% Vestal Point Capital, LP 31 Mar 2026
TYRA Tyra Biosciences, Inc. Common Stock, par value $0.0001 per share 4.5% $33,925,750 -$6,363,058 2,425,000 -16% Vestal Point Capital, LP 30 Sep 2025
NYXH Nyxoah SA Ordinary Shares, no nominal value per share 3.7% $10,599,135 -$6,932,157 1,402,002 -40% Vestal Point Capital, LP 30 Jun 2025
IMCR Immunocore Holdings plc American Depository Shares, each representing one ordinary share, nominal value 0.002 euro per share 3.5% $57,492,000 -$30,881,764 1,800,000 -35% Vestal Point Capital, LP 30 Jun 2026
DNTH Dianthus Therapeutics, Inc. /DE/ Common Stock, par value $0.001 per share 3% $46,433,000 -$79,487,000 1,180,000 -63% Vestal Point Capital, LP 30 Sep 2025
SVRA Savara Inc Common Stock, par value $0.001 per share 2.3% $14,333,550 -$24,133,200 4,015,000 -63% Vestal Point Capital, LP 30 Sep 2025
ANRO Alto Neuroscience, Inc. Common Stock, par value $0.0001 per share 2.2% $20,174,500 -$32,872,228 785,000 -62% Vestal Point Capital, LP 30 Jun 2026
KALV KalVista Pharmaceuticals, Inc. Common Stock, par value $0.001 per share 1.5% $9,135,000 750,000 Vestal Point Capital, LP 30 Sep 2025
BDTX Black Diamond Therapeutics, Inc. Common Stock, par value $0.0001 per share 1.5% $2,166,300 870,000 Vestal Point Capital, LP 31 Dec 2025
QURE uniQure N.V. Ordinary Shares, par value 0.05 euro per share 0.4% $13,133,250 -$202,835,750 225,000 -94% Vestal Point Capital, LP 30 Sep 2025
APLT Applied Therapeutics, Inc. Common Stock, par value $0.0001 per share 0% $0 -$1,150,000 0 -100% Vestal Point Capital, LP 31 Dec 2025
PASG Passage BIO, Inc. Common Stock, par value $0.0001 per share 0% $0 0 Vestal Point Capital, LP 30 Jun 2026
ACLX Arcellx, Inc. Common Stock, par value $0.001 per share 0% $0 -$335,848,500 0 -100% Vestal Point Capital, LP 31 Mar 2026
ATXS Astria Therapeutics, Inc. Common Stock, par value $0.001 per share 0% $0 -$63,040,320 0 -100% Vestal Point Capital, LP 31 Dec 2025

Schedules 13D/G Reported by Vestal Point Capital, LP:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .